Purdue Patents for Extended-Release OxyContin Nixed in Intas Win

A federal judge voided five patents Purdue Pharma LP alleges are infringed by generic versions of extended-release OxyContin proposed by Intas Pharmaceuticals Ltd.’s Accord unit, finding they cover obvious inventions and shouldn’t have been issued.

“This is not a case where a POSA”—a person of skill in the art, or an expert in the field—“would have to repeatedly choose correctly in a branching maze of paths forward,” Judge Richard G. Andrews wrote, referring to two of the canceled patents in an opinion issued Tuesday in the US District Court for the District of Delaware.

“Instead, Defendant presented clear and ...